Observational studyInternational journal of radiation oncology, biology, physics2018
Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer.
Observational study in International journal of radiation oncology, biology, physics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06686043 (A Phase 2 Study of HPV L1 Vaccine in Combination With Imiquimod and Metformin in Cervical, Vaginal, and Vulvar Cancers), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Study of HPV L1 Vaccine in Combination With Imiquimod and Metformin in Cervical, Vaginal, and Vulvar Cancers
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- Synergistic neoadjuvant radioimmunotherapy in locally advanced rectal cancer: mechanisms of pathologic response and the shift toward organ preservation.Frontiers in immunology · 2026Review
- Immune remodeling during cervical cancer chemoradiotherapy: temporal biomarkers and the timing of checkpoint blockade.Frontiers in immunology · 2026Review
- Apoptotic Macrophage-Derived Vesicles Loaded with Oncolytic Virus for Tumor Therapy.Cancer management and research · 2026Article
- Harnessing Oncolytic Viruses for Targeted Therapy in Triple-Negative Breast Cancer.International journal of medical sciences · 2025Review
- Prognostic value of neutrophil to lymphocyte ratio and lymphocyte counts before durvalumab consolidation after radio-chemotherapy in locally advanced non-small cell lung cancer.Radiation oncology (London, England) · 2024Article
- Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments.Cancer cell international · 2024Review
- Modulation of CD8International journal of molecular sciences · 2023Review
- Brachytherapy for targeting the immune system in cervical cancer patients.BMC immunology · 2023Article
- Review
- Circulating neutrophils and tumor-associated myeloid cells function as a powerful biomarker for response to chemoradiation in locally advanced cervical cancer.Clinical and translational radiation oncology · 2023Article
- Influence of chemoradiation on the immune microenvironment of cervical cancer patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Article
- Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer.Signal transduction and targeted therapy · 2023Article
- The current understanding of the immune landscape relative to radiotherapy across tumor types.Frontiers in immunology · 2023Review
- Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models.Frontiers in oncology · 2023Article
- Review
- A Review of the Effects of Cervical Cancer Standard Treatment on Immune Parameters in Peripheral Blood, Tumor Draining Lymph Nodes, and Local Tumor Microenvironment.Journal of clinical medicine · 2022Review
- Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?International journal of molecular sciences · 2022Review
- Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2022Article
- Multispectral Image under Tissue Classification Algorithm in Screening of Cervical Cancer.Journal of healthcare engineering · 2022Article
- Prognostic and therapeutic TILs of cervical cancer-Current advances and future perspectives.Molecular therapy oncolytics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
purposeRadiation therapy has direct cytotoxic effects on tumor-infiltrating lymphocytes, but it also has immune stimulatory effects that increase immune cell infiltration. The dynamics of these competing effects on immune cells at the site of the tumor are poorly characterized during chemoradiation treatment (CRT) because of the difficulty of obtaining consecutive tumor biopsies. We used a minimally invasive cervical cytobrushing method to analyze the kinetics of intratumoral immune cell changes in patients with cervical cancer during CRT. METHODS AND MATERIALS: Cervical brushings were obtained from 20 patients with cervical cancer at baseline and during fractionated radiation therapy and cisplatin (weeks 1, 3, and 5). Matching peripheral blood mononuclear cells were obtained from 9 patients at the same time points. Cells were analyzed using multispectral flow cytometry to identify T cell and myeloid cell subsets and their activation status. Changes in immune cell subsets throughout treatment were calculated using matched-pair analysis with Wilcoxon rank sum test.
resultsWe observed a significant decline in CD3+ total T cells, as well as CD8+ and CD4+ T-cell subsets in the first week of treatment from baseline, followed by variable expansion at weeks 3 and 5. This coincided with higher levels of proliferating CD8+ T cells expressing Ki67 at week 3 of treatment. The percentages of activated CD8+ T cells expressing CD69 continuously increased over the course of treatment, whereas the percentage of activated CD11c+CD11b- dendritic cells was highest during the first week. Many of these changes were not observed in the blood.
conclusionsOur results identified immune dynamic changes during CRT, indicating that CRT may be immune activating at the site of the tumor. This study also suggests the importance of sequential analyses of the local tumor microenvironment in addition to peripheral blood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.